Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,300 | 1,340 | 30.04. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
24.04. | Ocean Biomedical, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
24.04. | Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K | 434 | GlobeNewswire (Europe) | PROVIDENCE, Rhode Island, April 24, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq")... ► Artikel lesen | |
16.04. | Ocean Biomedical Inc reports results for the quarter ended in September - Earnings Summary | 3 | Reuters | ||
15.04. | Ocean Biomedical, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
15.04. | Ocean Biomedical, Inc. - 10-Q/A, Quarterly Report | 1 | SEC Filings | ||
04.04. | EQT In Exclusive Talks With ICG Infra To Acquire France's Ocea Group | 380 | AFX News | PARIS (dpa-AFX) - Natural gas producer EQT Corp. (EQT) announced Thursday its exclusive talks with ICG Infrastructure Equity I to buy Ocea Group, a French water and heat submetering infrastructure... ► Artikel lesen | |
04.04. | EQT enters exclusive talks with ICG Infra to acquire Ocea Group, a leading French water and heat submetering infrastructure provider | 272 | PR Newswire | Ocea is a provider of smart water and heat metering infrastructure in France, operating under long-term inflation-linked contracts in an industry benefiting from long term visibility and... ► Artikel lesen | |
01.04. | Ocean Biomedical, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 5 | SEC Filings | ||
28.03. | Ocean Biomedical, Inc.: Ocean Biomedical Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL | 97 | GlobeNewswire (Europe) | Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists... ► Artikel lesen | |
25.03. | Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview | 3 | Reuters | ||
18.03. | Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview | 2 | Reuters | ||
08.03. | Ocean Biomedical, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
08.03. | Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview | 4 | Reuters | ||
06.03. | OCEA, RVSN and HOVR among mid-day movers | 5 | Seeking Alpha | ||
29.02. | Ocean Biomedical, Inc.: Ocean Biomedical Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting | 27 | GlobeNewswire (USA) | ||
27.02. | HOLO, OCEA and ALPP among pre-market losers | 14 | Seeking Alpha | ||
20.02. | Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview | 24 | Reuters | ||
12.02. | Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview | 4 | Reuters | ||
17.01. | Ocean Biomedical, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
12.01. | Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview | 1 | Reuters |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,740 | +1,19 % | Kein Ausblick: Evotec crasht nach Zahlen um ein Drittel auf Tiefststand seit 2017 | © Foto: Breuel-Bild/dpaEvotec hat mit den Zahlen für das abgelaufene Jahr die Erwartungen enttäuscht und zudem noch keinen Ausblick geliefert. Was ist da los?Der Hamburger Wirkstoffforscher und -entwickler... ► Artikel lesen | |
MEDIGENE | 1,380 | -2,13 % | Aixtron, Deutsche Telekom, Infineon, Medigene, Nel ASA - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
CORE ONE LABS | 0,158 | +4,30 % | Sondermeldung: Gar mehrere hundert Prozent bis zur Bescherung? Wo die Community jetzt auf eine Jahresendrallye spekuliert… | ||
4SC | 8,040 | -3,83 % | 4SC vor entscheidenden Monaten: "Ein arbeitsreiches Quartal" | Das Biotech-Unternehmen 4SC hat am Donnerstag seine Quartalsmitteilung vorgelegt. Gemeldet wird zum 31. März ein Bestand an Finanzmitteln in Höhe von 6,1 Millionen Euro nach 8,3 Millionen Euro per Ende... ► Artikel lesen | |
BIOXXMED | 0,452 | -16,30 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei bioXXmed, Shelly Group, Valneva | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
ORGANOVO | 0,955 | -4,31 % | ORGANOVO HOLDINGS, INC. - 8-K, Current Report | ||
INOVIO PHARMACEUTICALS | 10,940 | -0,91 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grants Under Inducement Plan | PLYMOUTH MEETING, Pa., May 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related... ► Artikel lesen | |
CLINUVEL | 9,095 | +0,39 % | CLINUVEL PHARMACEUTICALS LIMITED: Syd Capital Markets Briefing Presentation | ||
SANGAMO THERAPEUTICS | 0,500 | +2,75 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
INFLARX | 1,300 | -0,54 % | InflaRx N.V.: InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event | ||
BIO-GATE | 1,010 | +2,02 % | EQS-News: Bio-Gate AG: Bio-Gate veröffentlicht Geschäftsbericht 2023 und bestätigt vorläufige Zahlen | EQS-News: Bio-Gate AG
/ Schlagwort(e): Jahresbericht/Prognose
Bio-Gate veröffentlicht Geschäftsbericht 2023 und bestätigt vorläufige Zahlen
30.04.2024 / 13:27 CET/CEST
Für... ► Artikel lesen | |
TREVENA | 0,382 | +2,96 % | Trevena, Inc.: Trevena Awarded OLINVYK Agreement with Premier, Inc. | CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
VIVORYON THERAPEUTICS | 0,660 | -0,30 % | Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates | Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,866 | +6,13 % | Defence Therapeutics Inc.: Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine | Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing... ► Artikel lesen | |
REDHILL BIOPHARMA | 0,414 | +2,48 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer |